PATENT CLAIM ANALYSIS

Application Number: 15991525
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["424", "490000"]

Abstract:
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Claim (Index 97):
The method of  claim 96 , wherein the antibody comprises a light chain variable region comprising at least one light chain framework residue selected from the group consisting of +75 and +92 (linear numbering) of SEQ ID NO: 152 occupied by Y and F, respectively, wherein the remainder of the light chain variable region is occupied by a corresponding residue in a human acceptor immunoglobulin light chain variable region.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.64583
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12811049', '13314160', '12345650', '13187093', '13032412']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.863164934686865
- 35 USC 102 Novelty (BERT): 0.6316116485389783
- Combined Prediction Score: 0.8400096060720763
- Mean Citation Score: 793.570468
- Max Citation Score: 823.9013
- Similarity Product: 528.162452999264

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test